2024
Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice
Thomas J, Schindler E, Gottschalk C. Meningeal lymphatic vessel dysfunction driven by CGRP signaling causes migraine-like pain in mice. Journal Of Clinical Investigation 2024, 134: e182556. PMID: 39087472, PMCID: PMC11290958, DOI: 10.1172/jci182556.Peer-Reviewed Original ResearchConceptsBlocking CGRP signalingCGRP receptor componentsMigraine-like painCervical lymph nodesGap junction proteinPrimary headache disordersLymphatic vessel dysfunctionAcute migrainePharmacological blockadeLymph nodesHeadache disordersNeurological symptomsJunction proteinsCGRPLymphatic vesselsMeningeal lymphatic vesselsInducible knockoutVessel dysfunctionMigraineReceptor componentsHeadachePainPathophysiologyDysfunctionMicePsychotropic Drugs Reemerging as Headache Medicines
Schindler E. Psychotropic Drugs Reemerging as Headache Medicines. CNS Drugs 2024, 38: 661-670. PMID: 39037675, DOI: 10.1007/s40263-024-01107-x.Peer-Reviewed Original ResearchManaging Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities
Burish M, Guirguis A, Schindler E. Managing Cluster Headache in Patients with Medical, Psychiatric, and Surgical Comorbidities. Current Neurology And Neuroscience Reports 2024, 24: 439-452. PMID: 39017830, DOI: 10.1007/s11910-024-01362-x.Peer-Reviewed Original ResearchPsilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial
Schindler E, Sewell R, Gottschalk C, Flynn L, Zhu Y, Pittman B, Cozzi N, D'Souza D. Psilocybin pulse regimen reduces cluster headache attack frequency in the blinded extension phase of a randomized controlled trial. Journal Of The Neurological Sciences 2024, 460: 122993. PMID: 38581739, DOI: 10.1016/j.jns.2024.122993.Peer-Reviewed Original ResearchConceptsAttack frequencyCluster headacheCluster headache attack frequencyExtension phaseEffects of repeated treatmentReduction of attack frequencyPlacebo-controlled studyHeadache attack frequencyAdministration of psilocybinRandomized controlled trialsDouble-blindPsilocybin administrationPulse regimenAdverse eventsPulse regimensHeadache diaryTherapeutic efficacyDrug sessionsPulse administrationHeadacheStudy participantsWeeks
2023
Studying classic psychedelics for the management of headache disorders: Considerations for Veterans
Schindler E, Sico J. Studying classic psychedelics for the management of headache disorders: Considerations for Veterans. Journal Of Military Veteran And Family Health 2023, 9: 88-95. DOI: 10.3138/jmvfh-2023-0006.Peer-Reviewed Original ResearchHeadache disordersCluster headacheLysergic acid diethylamideTreatment optionsBrain injuryTherapeutic effectAcid diethylamideTraumatic brain injuryConventional treatment optionsTrials of psilocybinMilitary membersPoor qualityPsychedelic drugsSummary PatientsHead traumaAvailable treatmentsHeadache managementHeadache treatmentCommon conditionHigh riskSide effectsSignificant disabilityHeadacheMore researchPoor efficacyAdapting psychedelic medicine for headache and chronic pain disorders
Schindler E, Hendricks P. Adapting psychedelic medicine for headache and chronic pain disorders. Expert Review Of Neurotherapeutics 2023, 23: 867-882. PMID: 37652000, DOI: 10.1080/14737175.2023.2246655.Peer-Reviewed Original ResearchConceptsChronic pain disordersPain disordersHeadache disordersChronic pain patientsRecent case reportsDifferent treatment paradigmsPsychedelic medicineSubstance use disordersMechanism of actionPain patientsChronic painCase reportClinical trialsTreatment paradigmTreatment outcomesTherapeutic effectLarge dosesUse disordersAdjunctive psychotherapyTherapeutic outcomesHeadacheBeneficial effectsSubjective effectsBranches of medicineDisordersUnderstanding headache classification coding within the veterans health administration using ICD-9-CM and ICD-10-CM in fiscal years 2014–2017
Fodeh S, Fenton B, Wang R, Skanderson M, Altalib H, Kuruvilla D, Schindler E, Haskell S, Brandt C, Sico J. Understanding headache classification coding within the veterans health administration using ICD-9-CM and ICD-10-CM in fiscal years 2014–2017. PLOS ONE 2023, 18: e0279163. PMID: 36598881, PMCID: PMC9812322, DOI: 10.1371/journal.pone.0279163.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationHeadache diagnosisICD-10-CMICD-10-CM diagnosisICD-10-CM codingSpecialty care clinicsSpecific headache diagnosesICD-9-CM codingDifferent headache typesICD-9-CMRace/ethnicityHeadache comorbidityHeadache NOSPatient ageCare clinicsChronic conditionsHeadache typesProvider typeSociodemographic factorsHealth AdministrationDiagnosisTwo yearsHeadachePatientsMigraine
2022
Recent advances in the diagnosis and management of cluster headache
Schindler EAD, Burish MJ. Recent advances in the diagnosis and management of cluster headache. The BMJ 2022, 376: e059577. PMID: 35296510, DOI: 10.1136/bmj-2020-059577.Peer-Reviewed Original ResearchConceptsCluster headacheHeadache disordersIpsilateral autonomic featuresChronic cluster headacheEpisodic cluster headachePrimary headache disordersFacial painDiagnostic delayTrigeminal neuralgiaSecondary causesTherapeutic featuresEffective treatmentUnilateral attacksHeadacheProper diagnosisNew treatmentsSuicidal ideationAutonomic featuresPainful human experiencesDisordersDiagnosisHigh rateRecent updatesTreatmentRecent advances
2021
Cluster Headache: Clinical Characteristics and Opportunities to Enhance Quality of Life
Grinberg AS, Best RD, Min KM, Schindler EAD, Koo BB, Sico JJ, Seng EK. Cluster Headache: Clinical Characteristics and Opportunities to Enhance Quality of Life. Current Pain And Headache Reports 2021, 25: 65. PMID: 34668084, DOI: 10.1007/s11916-021-00979-8.Peer-Reviewed Original ResearchConceptsQuality of lifeCluster headacheCommon psychiatric comorbiditiesCurrent clinical carePsychological treatmentPrimary headache disordersRecent FindingsPeopleClinical characteristicsSevere painPsychiatric comorbidityDisease burdenHeadache disordersClinical careDepressive symptomsGeneral populationHeadacheSuicidal ideationAutonomic featuresBehavioral interventionsCommitment TherapyPsychological factorsTreatmentBurdenComorbiditiesPain“You will eat shoe polish if you think it would help”—Familiar and lesser‐known themes identified from mixed‐methods analysis of a cluster headache survey
Schindler EAD, Cooper V, Quine DB, Fenton BT, Wright DA, Weil MJ, Sico JJ. “You will eat shoe polish if you think it would help”—Familiar and lesser‐known themes identified from mixed‐methods analysis of a cluster headache survey. Headache The Journal Of Head And Face Pain 2021, 61: 318-328. PMID: 33502769, DOI: 10.1111/head.14063.Peer-Reviewed Original ResearchConceptsCluster headache patientsCluster headacheHeadache patientsExercise/physical activityVitamins/supplementsSevere painInterventional investigationDisease management approachTreatment optionsSubgroup analysisPhysical activitySide effectsPatients' thoughtsMixed-methods analysisSecondary analysisFree-text responsesHeadachePatientsIllicit substancesDisease managementAdult participantsHeadache medicine
2018
Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics
Schindler EAD, Wallace RM, Sloshower JA, D’Souza D. Neuroendocrine Associations Underlying the Persistent Therapeutic Effects of Classic Serotonergic Psychedelics. Frontiers In Pharmacology 2018, 9: 177. PMID: 29545753, PMCID: PMC5838010, DOI: 10.3389/fphar.2018.00177.Peer-Reviewed Original ResearchCluster headacheClassic serotonergic psychedelicsPersistent therapeutic effectEffects of psychedelicsPotential long-term effectsPsychedelic drugsSystem involvementHeadache disordersTherapeutic resultsPsychedelic-assisted therapyDrug classesTherapeutic effectLong-term effectsMood disordersTherapeutic benefitMethodologic considerationsNeuropsychiatric disordersNeuroendocrine systemPsychedelic effectsHeadacheBeneficial effectsSerotonergic psychedelicsDisordersDrugsRecent reports
2015
Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey
Schindler EA, Gottschalk CH, Weil MJ, Shapiro RE, Wright DA, Sewell RA. Indoleamine Hallucinogens in Cluster Headache: Results of the Clusterbusters Medication Use Survey. Journal Of Psychoactive Drugs 2015, 47: 372-381. PMID: 26595349, DOI: 10.1080/02791072.2015.1107664.Peer-Reviewed Original ResearchConceptsCluster headacheIndoleamine hallucinogensConventional medicationsChronic cluster headachePain syndromePreventative medicationsAlternative medicationsLysergic acid diethylamideHeadache clinicConventional therapyCluster periodHeadacheMedicationsFinal analysisAcid diethylamideHallucinogensFurther investigationMost responsesSignificant numberAdditional evidenceParticipantsRemissionPatientsSyndromeClinic